Free Trial
NASDAQ:OPRX

OptimizeRx (OPRX) Stock Price, News & Analysis

OptimizeRx logo
$5.15
-0.07 (-1.34%)
(As of 11/1/2024 ET)

About OptimizeRx Stock (NASDAQ:OPRX)

Key Stats

Today's Range
$5.13
$5.26
50-Day Range
$5.15
$8.41
52-Week Range
$5.13
$16.65
Volume
116,552 shs
Average Volume
127,221 shs
Market Capitalization
$94.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.50
Consensus Rating
Moderate Buy

Company Overview

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.

OptimizeRx Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
52nd Percentile Overall Score

OPRX MarketRank™: 

OptimizeRx scored higher than 52% of companies evaluated by MarketBeat, and ranked 500th out of 667 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    OptimizeRx has only been the subject of 2 research reports in the past 90 days.

  • Read more about OptimizeRx's stock forecast and price target.
  • Earnings Growth

    Earnings for OptimizeRx are expected to grow in the coming year, from ($0.33) to ($0.28) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OptimizeRx is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OptimizeRx is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    OptimizeRx has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about OptimizeRx's valuation and earnings.
  • Percentage of Shares Shorted

    5.75% of the float of OptimizeRx has been sold short.
  • Short Interest Ratio / Days to Cover

    OptimizeRx has a short interest ratio ("days to cover") of 7.2.
  • Change versus previous month

    Short interest in OptimizeRx has recently increased by 8.71%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    OptimizeRx does not currently pay a dividend.

  • Dividend Growth

    OptimizeRx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.75% of the float of OptimizeRx has been sold short.
  • Short Interest Ratio / Days to Cover

    OptimizeRx has a short interest ratio ("days to cover") of 7.2.
  • Change versus previous month

    Short interest in OptimizeRx has recently increased by 8.71%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    OptimizeRx has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Computer and Technology companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for OptimizeRx this week, compared to 2 articles on an average week.
  • Search Interest

    7 people have searched for OPRX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OptimizeRx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.10% of the stock of OptimizeRx is held by insiders.

  • Percentage Held by Institutions

    76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about OptimizeRx's insider trading history.
Receive OPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.

OPRX Stock News Headlines

OptimizeRx: A Strong Buy on Client Commitments and Growth Potential
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines

OPRX Stock Analysis - Frequently Asked Questions

OptimizeRx's stock was trading at $14.31 at the beginning of the year. Since then, OPRX shares have decreased by 64.0% and is now trading at $5.15.
View the best growth stocks for 2024 here
.

OptimizeRx Co. (NASDAQ:OPRX) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.11. The company earned $18.81 million during the quarter, compared to analyst estimates of $20.47 million. OptimizeRx had a negative net margin of 21.53% and a negative trailing twelve-month return on equity of 5.97%.

OptimizeRx's top institutional shareholders include Rice Hall James & Associates LLC (3.36%), Essex Investment Management Co. LLC (1.32%), Janney Montgomery Scott LLC (0.57%) and Greenwood Capital Associates LLC (0.37%). Insiders that own company stock include William J Febbo, James Paul Lang, Marion Odence-Ford, Stephen L Silvestro, Edward Stelmakh, Ellen O'connor Vos, Patrick D Spangler and Miriam J Paramore.
View institutional ownership trends
.

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
8/08/2024
Today
11/02/2024
Next Earnings (Confirmed)
11/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
Business Services
Current Symbol
NASDAQ:OPRX
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.50
High Stock Price Target
$18.50
Low Stock Price Target
$11.00
Potential Upside/Downside
+181.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-17,570,000.00
Pretax Margin
-31.60%

Debt

Sales & Book Value

Annual Sales
$83.20 million
Book Value
$6.97 per share

Miscellaneous

Free Float
17,204,000
Market Cap
$94.36 million
Optionable
Optionable
Beta
1.27
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:OPRX) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners